Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Warp Speed’s Woodcock Encourages Institutions To Continue COVID-19 Plasma Controlled Trial

Executive Summary

Seeking to prevent negative fallout from emergency use authorization, Woodcock and NIH Director Collins ask investigators to prioritize a controlled trial of convalescent plasma currently underway in outpatients.

You may also be interested in...



Email Trove From US FDA Shows Peter Marks As Champion For Plasma Authorization

The emergency use authorization for convalescent plasma in August 2020 on weak data from an expanded access program has largely been viewed as a politically charged decision by the Trump administration. But newly revealed emails from the run up to the decision indicate Center for Biologics Evaluation and Research Director Peter Marks backed the plan.

Early ‘Scattershot’ Approach To COVID-19 Therapeutic Research Generated Little Actionable Data

US FDA and NIH leaders cite lack of early clinical trial coordination as a weakness in the pandemic response that led to use of compounds that were potentially harmful and, even today, still not proven to be effective.

Initial COVID-19 Vaccine Rollout Seems Bound To Disappoint

National Academy of Medicines draft on equitable COVID-19 vaccine allocation needs more overt strategies to address equity, commenters say. Meanwhile, competing national and state efforts to address COVID-19 vaccination allocation could lead to confusion as the country struggles to fairly divide limited resources among many high-risk populations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel